Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Voyager Therapeutics, Inc. (VYGR)  
$8.57 0.20 (2.28%) as of 4:30 Wed 5/8


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 37,470,000
Market Cap: 321.12(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $6.28 - $13.99
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Voyager Therapeutics is a gene therapy company focused on developing treatments and platform technologies. Co.'s team has developed a proprietary adeno-associated virus (AAV) capsid discovery platform called TRACER™ (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) to facilitate the selection of AAV capsids with blood brain barrier crossing and cell-specific transduction properties for particular therapeutic applications. The TRACER discovery platform is a functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 4,872,988
Total Buy Value $0 $0 $0 $41,694,868
Total People Bought 0 0 0 2
Total Buy Transactions 0 0 0 3
Total Shares Sold 38,202 42,011 76,578 2,756,162
Total Sell Value $317,473 $344,745 $641,708 $21,052,273
Total People Sold 4 4 4 9
Total Sell Transactions 7 9 13 45
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 162
  Page 2 of 7  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Carter Todd Alfred Chief Scientific Officer   •       –      –    2023-03-20 4 AS $7.76 $17,018 D/D (2,193) 65,360 17%     
   Hesslein Robert W. Senior VP & General Counsel   •       –      –    2023-03-20 4 AS $7.76 $34,222 D/D (4,410) 102,200 17%     
   Swartz Robin Chief Operating Officer   •       –      –    2023-03-15 4 S $8.20 $126,059 D/D (15,373) 76,530 -12%     
   Onyia Jude Director   –       •      –    2023-02-23 3 IO $0.00 $0 D/D 0 2,910 60%     
   Neurocrine Biosciences Inc 10% Owner   –       –       •   2023-02-23 4 B $8.88 $39,032,821 D/D 4,395,588 8,575,316 2.45 60%     
   Sandrock Alfred President and CEO   •       •      –    2023-02-17 4 A $0.00 $0 D/D 120,000 222,055     -
   Pfreundschuh Peter P. Chief Financial Officer   •       –      –    2023-02-17 4 A $0.00 $0 D/D 38,000 163,000     -
   Hesslein Robert W. Senior VP & General Counsel   •       –      –    2023-02-17 4 AS $7.45 $24,563 D/D (3,297) 106,610 54%     
   Carter Todd Alfred Chief Scientific Officer   •       –      –    2023-02-17 4 AS $7.45 $5,498 D/D (738) 67,553 54%     
   Carter Todd Alfred Chief Scientific Officer   •       –      –    2023-02-17 4 A $0.00 $0 D/D 34,000 68,291     -
   Swartz Robin Chief Operating Officer   •       –      –    2023-02-17 4 A $0.00 $0 D/D 40,000 91,903     -
   Carter Todd Alfred Chief Scientific Officer   •       –      –    2023-02-13 4 AS $7.67 $6,113 D/D (797) 34,291 53%     
   Hesslein Robert W. Senior VP & General Counsel   •       –      –    2023-02-13 4 AS $7.67 $21,998 D/D (2,868) 109,907 53%     
   Tepper Robert I 10% Owner   –       –       •   2023-02-02 4 D $0.00 $0 D/D (1,500,000) 3,185,291     -
   Tepper Robert I 10% Owner   –       –       •   2023-02-01 4 S $9.32 $1,198,943 D/D (128,642) 4,685,291 -41%     
   Tepper Robert I 10% Owner   –       –       •   2023-01-31 4 S $9.25 $1,711,250 D/D (185,000) 4,813,933 -37%     
   Tepper Robert I 10% Owner   –       –       •   2023-01-30 4 S $9.03 $677,250 D/D (75,000) 4,998,933 -41%     
   Tepper Robert I 10% Owner   –       –       •   2023-01-27 4 S $9.02 $451,000 D/D (50,000) 5,073,933 -40%     
   Tepper Robert I 10% Owner   –       –       •   2023-01-25 4 S $9.22 $461,000 D/D (50,000) 5,123,933 -29%     
   Tepper Robert I 10% Owner   –       –       •   2023-01-24 4 S $9.27 $927,000 D/D (100,000) 5,173,933 -20%     
   Tepper Robert I 10% Owner   –       –       •   2023-01-23 4 S $9.06 $498,300 D/D (55,000) 5,273,933 -28%     
   Tepper Robert I 10% Owner   –       –       •   2023-01-20 4 S $9.15 $915,000 D/D (100,000) 5,328,933 -24%     
   Hesslein Robert W. Senior VP & General Counsel   •       –      –    2023-01-17 4 AS $9.57 $21,549 D/D (2,188) 112,775 30%     
   Carter Todd Alfred Chief Scientific Officer   •       –      –    2023-01-17 4 AS $9.57 $10,892 D/D (1,106) 35,088 30%     
   Swartz Robin Chief Operating Officer   •       –      –    2023-01-17 4 AS $9.57 $21,549 D/D (2,188) 51,903 30%     
  162 Records found
  1  2  3  4  5  6  7   
  Page 2 of 7
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us